Novo Nordisk decodes India’s obesity drug market with Wegovy positioned as once-a-week novel weight management medication
Novo Nordisk, the Danish pharma major has launched Wegovy an injectable semaglutide in India. The ethically promoted Wegovy which is a once-weekly glucagon-like peptide-1 receptor agonist GLP-1 RA is the first and only weight management medication in India for both long-term chronic weight management and reduction in risk of cardiovascular events. It is available in five dosing strengths with the convenience of an innovative easy-to-use pen device.
• India has the third highest number of overweight and obesity cases.
• Alarmingly, obesity is associated with over 200 diseases, including cardiovascular diseases, certain types of cancer, and type 2 diabetes.
• Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, improving satiety and reducing cravings for food, eventually inducing weight-loss.
• It also improves insulin resistance and has a beneficial effect on reduction of cardiometabolic events and risk factors.
• The drug in India has undergone phase III trials on 3500 patients, said Vikrant Shrotriya, managing director, Novo Nordisk India at a press briefing in-person and online.
• Semaglutide is the active ingredient in both Ozempic and Wegovy.
• While Ozempic in many countries across the world is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.
• Wegovy is indicated for weight management and reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.
• Ozempic and Wegovy have been studied extensively in different trial participants and are indicated for different uses, as well as available in different dosages.
• Ozempic is not yet available in India.
• It is strongly advised that people with overweight or obesity speak to their doctor for appropriate treatment options, said the company.
• “Obesity is not just a personal health concern. It is a chronic disease and a national epidemic that India cannot afford to ignore. Recognising this, we are bringing Wegovy to Indians as a transformative and evidence-based therapeutic solution with the convenience of a world-class, state-of-the-art pen device.”
• “Additionally, we have an India-specific price with the benefit of same price for the first three dosing strengths. With this we are reaffirming our commitment to address India's growing burden of overweight and obesity,” said Shrotriya.
• Wegovy will be available in a once-weekly innovative pen device in five dose strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and a maintenance dosing of 2.4 mg.
• The state-of-the-art pen device provides the convenience of simple administration and precise dosing.
• It is priced at Rs. 17,345 for 0.25, 0.5 and 1mg.
• The doses in 1.7 mg costs Rs. 24,280 and 2.4 mg is Rs. 26,050, said the Novo Nordisk India chief.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!